ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,979.46
      -0.10%
      US Tech 100
      20,460.00
      -0.15%
      Dow Jones
      43,939.56
      -0.04%
      Brent Oil
      72.695
      1.15%
      Bitcoin
      88,148.40
      -2.67%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Moderna Inc (MRNA) Quote

      Moderna Inc

      Moderna Inc (MRNA)

      NASDAQ
      40.96
      -1.18
      ( -2.80% )
      Updated: 10:46:55
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      40.96
      Bid
      40.95
      Ask
      40.98
      Volume
      2,665,461
      40.24 Day's Range 42.10
      40.24 52 Week Range 170.47
      Market Cap
      15.745B
      Previous Close
      42.14
      Open
      42.10
      Last Trade
      100
      @
      40.96
      Last Trade Time
      10:46:55
      Financial Volume
      $ 108,806,498
      VWAP
      40.8209
      Average Volume (3m)
      5,878,416
      Shares Outstanding
      384,396,030
      Dividend Yield
      -
      PE Ratio
      -3.38
      Earnings Per Share (EPS)
      -12.26
      Revenue
      6.85B
      Net Profit
      -4.71B

      About Moderna Inc

      Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of ... Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases. Show more

      Sector
      Biological Pds,ex Diagnstics
      Industry
      Biological Pds,ex Diagnstics
      Website
      www.modernatx.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Moderna Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker MRNA. The last closing price for Moderna was $42.14. Over the last year, Moderna shares have traded in a share price range of $ 40.24 to $ 170.47.

      Moderna currently has 384,396,030 shares outstanding. The market capitalization of Moderna is $16.20 billion. Moderna has a price to earnings ratio (PE ratio) of -3.38.

      Ask ADVFN Intelligence (AI)

      Moderna (MRNA) Options Flow Summary

      MRNA Options Flow

      Overall Flow

      Bearish

      Net Premium

      -5M

      Calls / Puts

      14.15%

      Buys / Sells

      87.30%

      OTM / ITM

      16.35%

      Sweeps Ratio

      0.83%

      MRNA Latest News

      More News

      Form 4 - Statement of changes in beneficial ownership of securities

      November 12 2024
      Edgar (US Regulatory)

      Form 144 - Report of proposed sale of securities

      November 12 2024
      Edgar (US Regulatory)

      Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma

      Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma PR Newswire PHILADELPHIA, Nov. 8, 2024 New findings showcase the potential of in vivo...

      November 08 2024
      PR Newswire (US)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      November 07 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      November 07 2024
      Edgar (US Regulatory)

      U.S. Futures Rise as Investors Await Fed Rate Decision; Oil Prices Drop

      U.S. index futures rose in Thursday’s pre-market session following Donald Trump’s victory, which sent the Dow Jones up over 1,500 points yesterday. Investors are watching for the Federal...

      November 07 2024
      IH Market News

      Trump Media Shares Surge 32% Pre-Market; Tesla Jumps 13%; Coinbase Rises with BTC All-Time High

      Trump Media & Technology Group (NASDAQ:DJT) – Donald Trump’s media company reported a $19.2 million loss in Q3, driven by $12.1 million in legal fees tied to a streaming deal and SPAC...

      November 06 2024
      IH Market News

      Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024

      Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024 PR Newswire PHILADELPHIA, Nov. 5, 2024 Pre-clinical data demonstrate robust...

      November 05 2024
      PR Newswire (US)

      Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)

      The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program, as the third Phase 3 trial for the investigational individualized neoantigen therapy, V940...

      October 28 2024
      Business Wire

      Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence

      Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence PR Newswire CAMBRIDGE, Masss. and LONDON, Oct...

      October 23 2024
      PR Newswire (US)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-15.65-27.645292351256.6156.69540.241321992045.70556644CS
      4-16.39-28.578901482157.3557.6940.24707852950.00301723CS
      12-45.2-52.46053853386.1686.840.24587841660.67199836CS
      26-86.04-67.7480314961127170.4740.24492809488.58140307CS
      52-32.7-44.393157751873.66170.4740.24461346893.36530507CS
      156-190.04-82.2683982684231376.411840.245227686146.7472113CS
      26022.8125.55066079318.16497.1717.689145190147.06747561CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      PULMPulmatrix Inc
      $ 6.18
      (73.60%)
      		8.33M
      OMEROmeros Corporation
      $ 7.1173
      (69.86%)
      		6.51M
      QUBTQuantum Computing Inc
      $ 3.8912
      (46.29%)
      		117.17M
      XTIAXTI Aerospace Inc
      $ 0.0762
      (33.22%)
      		270.98M
      AGFYAgrify Corporation
      $ 13.4734
      (29.18%)
      		225.08k
      SOWGSow Good Inc
      $ 4.595
      (-53.16%)
      		967.8k
      NVCTNuvectis Pharma Inc
      $ 5.855
      (-45.13%)
      		968.81k
      TRNRInteractive Strength Inc
      $ 3.6801
      (-36.88%)
      		1.05M
      OPRXOptimizeRx Corporation
      $ 4.335
      (-29.51%)
      		567.91k
      JTAIJet AI Inc
      $ 5.73
      (-29.43%)
      		209k
      ELABElevai Labs Inc
      $ 0.03
      (21.46%)
      		1.33B
      XTIAXTI Aerospace Inc
      $ 0.0762
      (33.22%)
      		270.98M
      SVMHSRIVARU Holding Ltd
      $ 0.0299
      (23.55%)
      		186.85M
      QUBTQuantum Computing Inc
      $ 3.8912
      (46.29%)
      		117.17M
      MVSTMicrovast Holdings Inc
      $ 0.8699
      (9.41%)
      		116.88M

      MRNA Discussion

      View Posts
      axelvento axelvento 11 hours ago
      next-
      https://www.theguardian.com/society/2024/oct/23/doctors-trial-worlds-first-vaccine-against-vomiting-bug-norovirus
      👍️ 2 🔜 1
      Vexari Vexari 1 day ago
      The majority shareholder of Moderna is?

      When you are suffering

      They are profiting
      👇️ 1 🗑️ 1 🚽 1 🤪 1 🧻 1
      axelvento axelvento 2 days ago
      https://www.biospace.com/job-trends/biospace-announces-2025-best-places-to-work-in-biopharma
      👋 1 👍 1
      axelvento axelvento 5 days ago
      Jpmorgan Chase & Co ownership in MRNA / Moderna, Inc.
      On November 8, 2024 - Jpmorgan Chase & Co filed a 13F-HR form disclosing ownership of 2,227,044 shares of Moderna, Inc. (US:MRNA) valued at $148,833,351 USD as of September 30, 2024. The entity filed a previous 13F-HR on August 12, 2024 disclosing 1,756,708 shares of Moderna, Inc.. This represents a change in shares of 26.77% during the quarter. The current value of the position is $104,292,471 USD.

      https://fintel.io/so/us/mrna/jpmorgan-chase-
      👍 2
      axelvento axelvento 5 days ago
      https://www.acsh.org/news/2024/11/07/dont-be-afraid-mrna-vaccines-49111
      👍️ 3 🤙 1
      axelvento axelvento 5 days ago
      Moderna Buys Norwood Campus for $400M

      https://bankerandtradesman.com/moderna-buys-norwood-campus-for-400m/#:~:text=Lab%20developer%20Alexandria%20Real%20Estate,core%20properties%20in%20Greater%20Boston.
      👍️ 3 😀 1
      axelvento axelvento 7 days ago
      Moderna (MRNA) Q3 2024 Earnings Call Transcript

      https://www.fool.com/earnings/call-transcripts/2024/11/07/moderna-mrna-q3-2024-earnings-call-transcript/
      👍️ 4 ✌️ 1
      EarningsCentral EarningsCentral 7 days ago
      👍️0
      axelvento axelvento 1 week ago
      MRNA is set to report third-quarter 2024 earnings on Nov. 7, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $1.25 billion and a loss of $1.91 per share, respectively
      👍️0
      axelvento axelvento 2 weeks ago
      Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)

      https://investors.modernatx.com/news/news-details/2024/Merck-and-Moderna-Initiate-Phase-3-Trial-Evaluating-Adjuvant-V940-mRNA-4157-in-Combination-with-KEYTRUDA-pembrolizumab-After-Neoadjuvant-KEYTRUDA-and-Chemotherapy-in-Patients-With-Certain-Types-of-Non-Small-Cell-Lung-Cancer-NSCLC/default.aspx


      huge news$
      👍️ 1 🤑 1
      axelvento axelvento 3 weeks ago
      https://www.investing.com/news/company-news/piper-sandler-maintains-overweight-rating-on-moderna-stock-93CH-3680972
      👋 1 👍️ 2
      axelvento axelvento 3 weeks ago
      20B market cap, 10B in cash, high potential pipeline in 4 therapeutic areas!
      👍️ 2 💪 1
      axelvento axelvento 3 weeks ago
      Moderna has a whopping 33 million short share interest, but daily volume now a paper-thin 3.7 million

      "Highest shorted stock on S&P500"
      👍️ 1 🤣 1 ☝️ 1
      axelvento axelvento 3 weeks ago
      MRNA December 6th Options Begin Trading

      https://www.nasdaq.com/articles/mrna-december-6th-options-begin-trading
      👍️0
      axelvento axelvento 3 weeks ago
      Moderna’s norovirus vaccine enters Phase III trials in the UK
      The firm hopes to file marketing applications in 2026 to have the vaccine approved by health regulators.

      https://www.clinicaltrialsarena.com/news/modernas-norovirus-vaccine-enters-phase-iii-trials-in-the-uk/
      👍️ 2 🤙 1
      Vexari Vexari 3 weeks ago
      Depends

      On the road

      That they're on
      👎️ 1 🗑️ 1 🚽 1 🧻 1 0️⃣ 1
      Vexari Vexari 3 weeks ago
      All that is marketed

      Is fear based
      🌬️ 1 🎃 1 👎️ 1 🕳️ 1 🗑️ 1
      gapole gapole 3 weeks ago
      looks like meltdown here. where is the bad news? $53.54
      👍️0
      Monksdream Monksdream 4 weeks ago
      MRNA new 52. Week low
      👍️0
      axelvento axelvento 4 weeks ago
      Moderna stock touches 52-week low. bouncer
      👍️0
      axelvento axelvento 4 weeks ago
      https://www.kcl.ac.uk/news/mrna-cancer-vaccine-potential-advanced-stage-cancer-patients-in-phase-1-trial
      👍️ 1 ✌️ 1
      jondoeuk jondoeuk 4 weeks ago
      I couldn't find a PR or the poster.
      👍️0
      Vexari Vexari 1 month ago
      Unraveling all the Lies of the Covid-19

      Psychological Operation
      👎️ 2 🗑️ 1 😎 1 🤥 1 🧻 1 0️⃣ 1
      axelvento axelvento 1 month ago
      $MRNA We are tackling cancer on an individual basis where we can take samples from each patient, understand their cancer, and design a therapy specifically for them

      https://www.fastcompany.com/91202048/the-mrna-advantage
      👍️ 1 🫨 1 ☝️ 1
      tmonkey tmonkey 1 month ago
      this one near a bottom-im in------tmonkey
      👍️0
      axelvento axelvento 1 month ago
      https://www.globenewswire.com/news-release/2024/10/04/2958235/0/en/Global-mRNA-Cancer-Vaccine-Clinical-Trial-FDA-Approval-Market-Size-Future-Opportunity-Companies-Insight.html

      $MRNA
      👍️ 1 🤑 1
      axelvento axelvento 1 month ago
      Join us on Nov 8, as we, alongside
      moderna_
      , share promising data on anti-GPC3 in vivo CAR-M therapy for HCC. We'll also present TIP poster for the Ph1 study of anti-HER2 CAR-Monocytes targeting solid tumors.

      https://ir.carismatx.com/news-releases/news-release-details/carisma-therapeutics-announces-upcoming-presentations-sitc-2024
      👍️ 1 😃 1
      axelvento axelvento 1 month ago
      back to the 23 November lows bounce spot watching either way to see if holds or breaks.
      👍️0
      axelvento axelvento 1 month ago
      We have put the mescaline to make you feel better-have a good trip$MRNA
      👍️ 2 😀 1
      axelvento axelvento 1 month ago
      With post hoc analysis....
      👍️ 2 🤑 1
      Vexari Vexari 1 month ago
      What's in this dose of Pivotal

      How does it affect the immune system

      Why not question what is being announced

      Instead of grabbing onto it

      Hook line and sinker
      👎️ 1 🗑️ 1 🤪 1 🧻 1 0️⃣ 1
      axelvento axelvento 1 month ago
      Moderna Announces First Participant Dosed in Pivotal Phase 3 Trial of Investigational mRNA Norovirus Vaccine, mRNA-1403

      https://investors.modernatx.com/news/news-details/2024/Moderna-Announces-First-Participant-Dosed-in-Pivotal-Phase-3-Trial-of-Investigational-mRNA-Norovirus-Vaccine-mRNA-1403/default.aspx
      👍️ 1 ✌️ 1
      axelvento axelvento 1 month ago
      Moderna and Cenra Healthcare Enter Joint Agreement to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Taiwan, Including COVID-19 Vaccines

      https://investors.modernatx.com/news/news-details/2024/Moderna-and-Cenra-Healthcare-Enter-Joint-Agreement-to-Promote-Modernas-mRNA-Respiratory-Vaccine-Portfolio-in-Taiwan-Including-COVID-19-Vaccines/default.aspx
      👍️0
      axelvento axelvento 1 month ago
      Multiple key late-stage readouts are on the way as well. Moderna should report phase 3 results for cytomegalovirus (CMV) vaccine mRNA-1647 as early as year-end. It's also on track to begin generating data later this year from pivotal studies of mRNA-3705 and mRNA-3927 targeting metabolic disorders methylmalonic acidemia and propionic acidemia, respectively.
      👍️ 2 😝 1
      axelvento axelvento 2 months ago
      First cancer vaccine may enter the market in 2025. Always keep that in mind
      👍️ 1 ✌️ 1
      axelvento axelvento 2 months ago
      Mr Justice Meade concluded one of the European Moderna patents, labelled EP565, was “invalid”.

      But the judge said a different patent, called EP949, was “valid” and was infringed by Pfizer and BioNTech.

      https://finance.yahoo.com/news/covid-19-vaccine-patent-legal-123139810.html

      full stop$$$$$$$
      👋 1 👍️ 1
      Vexari Vexari 2 months ago
      What happened to the NIH director

      So many have yet

      To be disclosed
      🎃 1 👎️ 1 🕳️ 1 🗑️ 1 🧻 1
      axelvento axelvento 2 months ago
      https://www.marketbeat.com/instant-alerts/nasdaq-mrna-sec-filing-2024-09-22/
      👍️0
      axelvento axelvento 2 months ago
      With Pfizer hitting a stumbling block, Moderna’s COVID-19/influenza vaccine, mRNA-1083, could be the first such combination vaccine to reach the market. In June, the company posted results from a Phase III trial that showed mRNA-1083 produced a strong immune response against both COVID-19 and influenza. In releasing the results, Moderna also became the first and, due to Pfizer/BioNTech’s struggles, only company to date to post positive Phase III results for a combination COVID-19/influenza vaccine.

      https://www.biospace.com/drug-development/5-late-stage-mrna-vaccines-to-watch
      👍️ 2 ✌️ 1
      DewDiligence DewDiligence 2 months ago
      That's a clcikbait article, IMO. NVO's working with a small company who has some expertise in RNA does not make NOVO a competitor of MRNA.
      👍️0
      axelvento axelvento 2 months ago
      Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks

      https://www.fool.com/investing/2024/09/19/novo-nordisk-just-took-a-530-million-step-onto-mod/

      $RELAX
      👍️0
      axelvento axelvento 2 months ago
      Buy the Fear, Sell the Greed$$$$$$
      👍️0
      Vexari Vexari 2 months ago
      That is the question

      Why does the NIH own half

      Of all MRNA injections
      👎️ 1 🗑️ 1 🤪 1 🧻 1 0️⃣ 1
      axelvento axelvento 2 months ago
      I do not know, what do you think? "It has to bounce back"
      👍️0
      axelvento axelvento 2 months ago
      Moderna was getting too big, too fast. "The size of our late-stage pipeline combined with the challenge of launching products means we must now focus on delivering these 10 products to patients, slow down the pace of new R&D investment, and build our commercial business," said chief executive officer Stéphane Bancel.
      This is after -- just last year -- forecasting the launch of as many as 15 new products over the next five years.

      THE WRITING IS ON THE WALL

      https://www.fool.com/investing/2024/09/14/after-moderna-shocking-news-is-stock-a-buy-or-sell/
      👍️ 1 😀 1
      Monksdream Monksdream 2 months ago
      MRNA how much lower can it go
      😎 1
      axelvento axelvento 2 months ago
      https://www.oncologypipeline.com/apexonco/accelerated-path-closes-modernamercks-immunotherapy

      The journey is long and full of dangers.

      The FDA’s issue with mRNA-4157 is unclear but it’s possible that, with the melanoma sector already well served, the agency is waiting for a clear overall survival benefit.
      👋 1 👍️ 1
      axelvento axelvento 2 months ago
      Scientists are hailing a new dawn in cancer treatment after a groundbreaking vaccine stopped the growth of tumours and the development of new ones in half of patients in the first-in-human study.

      The mRNA-4359 vaccine works by teaching the immune system to identify and attack cancer cells

      The work
      https://www.msn.com/en-gb/health/other/cancer-breakthrough-as-vaccine-revs-up-immune-system-to-stop-tumours-and-destroy-disease-in-world-first/ar-AA1qwwX1?apiversion=v2&noservercache=1&domshim=1&renderwebcomponents=1&wcseo=1&batchservertelemetry=1&noservertelemetry=1
      👍️0
      axelvento axelvento 2 months ago
      https://www.modernatx.com/en-US/media-center/all-media/blogs/strategic-priorities-at-R-D-Day
      👍️0
      axelvento axelvento 2 months ago
      Moderna is due to present the data from the first-in-human study of mRNA-4359 on 14 September at the European Society of Medical Oncology meeting, taking place between 13 September and 16 September in Barcelona, Spain.
      👍️0

      Your Recent History

      NASDAQ
      MRNA
      Moderna
      Delayed Upgrade Clock